Actos Bladder Cancer Lawsuits: Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Actos Litigation

Share Article

The Firm continues to investigate Actos lawsuits on behalf of patients who may have developed bladder cancer due to long-term use of Actos.

Actos bladder cancer lawsuits pending in a multidistrict litigation underway in U.S. District Court, Western District of Louisiana, continue to move forward, Bernstein Liebhard LLP reports. According to a calendar posted on the Court’s website, the next Status Conference in the federal Actos litigation has been scheduled for April 25, 2013. Court records indicate that Takeda Pharmaceuticals has been named in more than 3,000 Actos lawsuits, most of which are pending in the federal proceeding underway in Louisiana. (In re: Actos Product Liability Litigation, MDL No. 2299)

“We are pleased to see this litigation moving forward. We continue to receive inquiries from long-term Actos users who developed bladder cancer while using this drug,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free Actos bladder cancer lawsuit evaluations to individuals who were long-term users of the drug, and were diagnosed with the disease.

Actos Lawsuits

In June 2011, the U.S. Food & Drug Administration (FDA) ordered Takeda to add new warnings to the Actos label, after a study found that long-term use of the drug increased the risk for bladder cancer.* Since the FDA issued its Actos alert, the evidence tying Actos to an increased risk of bladder cancer has only grown.    Most recently, a study published in the British Diabetic Association journal, “Diabetic Medicine,” found that the risk of bladder cancer was significantly higher in patients using Actos compared with control groups.**

While court records indicate that the first bellwether trials in the federal Actos litigation will not begin until January 2014, the nation’s first trial involving an Actos bladder cancer lawsuit is already underway in Los Angeles Superior Court. (Cooper v. Takeda Pharmaceuticals America, Inc., CGC-12-518535, California Superior Court) According to a recent report, a clinical pharmacologist testified early in the proceeding that internal Takeda emails indicated the company was more concerned with profits than patient safety when officials discussed adding bladder cancer warnings to the Actos label. “Actos is the most important product for Takeda and therefore we need to manage this issue very carefully and successfully not to cause any damage for this product globally,” a Takeda executive wrote. Such a development would be a “worst case scenario,” and he urged colleagues to seek a “positive outcome” from “regulatory authorities,” Bloomberg said.***

Actos users who developed bladder cancer may be entitled to file an Actos lawsuit to obtain compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about filing an Actos bladder cancer lawsuit by visiting Bernstein Liebhard LLP’s website, or contact one of our attorneys by calling (877) 779-1414.


About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website